Incyte downgraded by Truist with a new price target
$INCY
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Truist downgraded Incyte from Buy to Hold and set a new price target of $74.00 from $83.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/29/2024 | $68.00 → $90.00 | Neutral → Buy | BofA Securities |
| 10/1/2024 | $84.00 | Outperform | Wolfe Research |
| 9/18/2024 | $83.00 → $74.00 | Buy → Hold | Truist |
| 7/2/2024 | $52.00 → $48.00 | Market Perform → Underperform | BMO Capital Markets |
| 5/23/2024 | $55.00 | Hold | Deutsche Bank |
| 4/23/2024 | Neutral | Cantor Fitzgerald | |
| 2/23/2024 | $81.00 | Buy | Jefferies |
| 2/14/2024 | Mkt Outperform → Mkt Perform | JMP Securities |
10-Q - INCYTE CORP (0000879169) (Filer)
8-K - INCYTE CORP (0000879169) (Filer)
10-Q - INCYTE CORP (0000879169) (Filer)
SC 13G - INCYTE CORP (0000879169) (Subject)
SC 13D/A - INCYTE CORP (0000879169) (Subject)
SC 13D/A - INCYTE CORP (0000879169) (Subject)
BofA Securities upgraded Incyte from Neutral to Buy and set a new price target of $90.00 from $68.00 previously
Wolfe Research initiated coverage of Incyte with a rating of Outperform and set a new price target of $84.00
Truist downgraded Incyte from Buy to Hold and set a new price target of $74.00 from $83.00 previously
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
4 - INCYTE CORP (0000879169) (Issuer)
Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling
Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy
Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
Incyte (NASDAQ:INCY) today announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU). The decision was made following the observation of certain in vivo preclinical toxicology findings. These data have been shared with the U.S. Food and Drug Administration (FDA) and Incyte will work closely with the FDA to determine next steps. Enrollment in the other INCB000262 proof-of-concept studies is complete and data from all clinical studies will help inform its future development and guide the potential development of back-up molecules. In addition, data from the Phase 2 study evaluating MRGPRX4 (INCB000547) in cholesta
Incyte (NASDAQ:INCY) announced today that it will present at Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 3:15 p.m. in Miami. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered i
Incyte (NASDAQ:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 33,003 shares of the Company's common stock and stock option awards to purchase an aggregate of 15,812 shares of the Company's common stock to 27 new employees. The awards were made under the Company's 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of November 1, 2024, and were approved by the compensation committee of the Company's board of directors as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU vests as to 25% of the shares subject
The S&P 500 index climbed to new all-time highs, rising 0.3% during Tuesday’s session, aiming for a potential sixth consecutive positive close and remaining resilient after Fed Chair Jerome Powell‘s testimony before the Senate Banking Committee. Powell used both hawkish tones – stating that it is not yet appropriate to cut rates until greater confidence on the 2% target is achieved – and dovish tones, noting recent progress and warning that a weakening labor market could be a significant factor for a rate cut. Markets are looking ahead with confidence to the upcoming June inflation report, due this Thursday, which could solidify the already high expectations for a rate cut in September
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Seaport Global analyst Jim Mitchell downgraded the rating for The Goldman Sachs Group, Inc. (NYSE:GS) from Buy to Neutral. Goldman Sachs shares fell 0.7% to trade at $460.26 on Tuesday. See how other analysts view this stock. UBS analyst David Vogt downgraded Pure Storage, Inc. (NYSE:PSTG) from Neutral to Sell, but raised the price target from $44 to $47. Pure Storage shares fell 4.8% to trade at $62.36 on Tuesday. See how other analysts view this stock. Citigroup analyst Anthony Pe
Total revenues of $1,138 million in the third quarter (Q3'24) (+24% Y/Y) Jakafi® (ruxolitinib) net product revenues of $741 million in Q3'24 (+16% Y/Y); raising full year 2024 Jakafi guidance to a new range of $2,740 - $2,770 million Opzelura® (ruxolitinib) cream net product revenues of $139 million in Q3'24 (+52% Y/Y); launch momentum continues in the U.S. supported by reimbursement expansion in Europe Niktimvo™ (axatilimab-csfr) approved by FDA for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients Regulatory and development progress with supplemental New Drug Application (sNDA) for ruxo
Incyte (NASDAQ:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 29, 2024. The schedule for the press release and conference call/webcast is as follows: • Q3 2024 Press Release: October 29, 2024 at 7:00 a.m. ET • Q3 2024 Conference Call: October 29, 2024 at 8:00 a.m. ET • Domestic Dial-In Number: 877-407-3042 • International Dial-In Number: 201-389-0864 • Conference ID Number: 13749146 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in
New antitumor response data from a range of doses and regimens unveiled today at Incyte investor event These results build upon safety and tolerability data presented earlier today during a mini-oral presentation at the European Society of Medical Oncology (ESMO) Congress 2024 Findings support the initiation of a pivotal trial in ovarian cancer, expected to begin in 2025; additional plans to evaluate INCB123667 in combination with other treatments are underway Incyte (NASDAQ:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with advanced solid tumors. The trial results, presented during a mini-oral p
Mechelen, Belgium; 12 June 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director. Dr. Schaffert replaces Dr. Rajesh Parekh who stepped down on 10 June 2023. After an extraordinary 27-year career at Novartis in various global roles, including commercialization, market access, investor relations, business development & licensing, acquisitions and company integration, Dr. Schaffert retired in 2022 as President of Novartis Oncology and Member of the Novartis Executive Committee. In that role, Dr. Schaffert ran a global $15 billion business acr
Incyte (NASDAQ:INCY) announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors. "On behalf of the Incyte Board of Directors, I am happy to welcome Susanne. Her extensive commercial, development and industry experience will greatly complement our Board and we look forward to Susanne's contributions to our continued growth and future success," said Hervé Hoppenot, Chief Executive Officer, Incyte. "I am very excited for the opportunity to join the Incyte Board of Directors and helping the organization in its commitment to leading scientific innovation and developing new medicines for patients in need. I look forward to being part of this dynamic Company
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr